Clostridium difficile infection recurrence
Infectious disease · 2017–2020
4decisions
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bezlotoxumab Prevention of Clostridium difficile infection (CDI) recurrence in patients aged 18 years or older with confirmed diagnosis of toxin B positive CDI, who are at… | Mar 2020 | Not recommended | none received |
| bezlotoxumab Prevention of Clostridium difficile infection (CDI) recurrence in patients aged 18 years or older with confirmed diagnosis of toxin B positive CDI who are at… | Jul 2019 | Not recommended | none received |
| bezlotoxumab Prevention of Clostridium difficile infection (CDI) recurrence in patients aged 18 years or older with confirmed diagnosis of toxin B positive CDI, who are at… | Jul 2018 | Not recommended | none received |
| bezlotoxumab Prevention of Clostridium difficile infection (CDI) recurrence in patients receiving antibiotic therapy for CDI. | Nov 2017 | Not recommended | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.